The FDA has granted priority review for intravenous tocilizumab to treat adults hospitalized with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation.
A final FDA decision on approval is expected in the second half of the year, according to a press release issued by Roche. Tocilizumab (Actemra, Genentech) is currently under an emergency use authorization for this indication in adults and children aged 2 years and older.
“The high rate of unvaccinated people will continue to put a strain on